Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTK6 | Q13882 | 1/20 | 0.45 |
| ▸ | TTK | P33981 | 3/20 | 0.45 |
| ▸ | CHRM1 | P11229 | 10/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.41 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.41 |
| ▸ | CNR2 | P34972 | 2/20 | 0.40 |
| ▸ | PTK2 | Q05397 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22123076 | 0.93 | TTK (0.47) | PTK6TTKCHRM1PTK2 | |
| SCHEMBL30171836 | 0.93 | TTK (0.47) | PTK6TTKCHRM1PTK2 | |
| SCHEMBL30171737 | 0.92 | TTK (0.42) | PTK6TTKCNR2 | |
| SCHEMBL22123494 | 0.92 | TTK (0.42) | PTK6TTKCNR2 | |
| SCHEMBL22122910 | 0.90 | PTK2 (0.46) | PTK6TTKCHRM1HTR4PTK2 | |
| SCHEMBL30172057 | 0.89 | PTK6 (0.43) | PTK6TTKCHRM1HTR3AHTR4 | |
| SCHEMBL22123426 | 0.89 | PTK6 (0.43) | PTK6TTKCHRM1HTR3AHTR4 | |
| SCHEMBL22123879 | 0.87 | PTK6 (0.48) | PTK6TTKCHRM1HTR3AHTR4 | |
| SCHEMBL22139108 | 0.86 | PTK2 (0.43) | PTK6TTKPTK2 | |
| SCHEMBL30171895 | 0.86 | PTK2 (0.43) | PTK6TTKPTK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230012368-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-12 | — | — | US | disclosed |
| US-20230012368-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2023-01-12 | — | — | US | disclosed |
| EP-3898631-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | F. Hoffmann-La Roche AG (CH) | 2021-10-27 | — | — | EP | disclosed |
| WO-2020126953-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES AS ANTIBACTERIALS | F. HOFFMANN-LA ROCHE AG (CH) | 2020-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230012368-A1 | NOVEL IMIDAZOPYRAZINE DERIVATIVES | MRPL21, MYD88, IL1R1 | PTK6 2211/4885TTK 4482/4885CHRM1 986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.